• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Ensoma

    News headline image
    Ensoma Announces First Patient Dosed in Phase 1/2 Clinical Trial of EN-374 for Treatment of X-CGD
    From Ensoma
    Via Business Wire
    News headline image
    Ensoma Presents Preclinical Data Demonstrating Potential of In Vivo, HSC-derived CAR-M, NK, and T Platform for Solid Tumors at SITC 2025
    From Ensoma
    Via Business Wire
    News headline image
    Ensoma to Present New Preclinical Data at the Society for Immunotherapy of Cancer Annual Meeting
    From Ensoma
    Via Business Wire
    News headline image
    Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline
    From Ensoma
    Via Business Wire
    News headline image
    Ensoma Announces FDA Clearance of IND Application for First In Vivo HSC-Directed Gene Insertion Therapy
    From Ensoma
    Via Business Wire
    News headline image
    Ensoma to Present Preclinical Data and Manufacturing Advancements for In Vivo HSC Engineering Platform to Treat Cancer, Immune Disorders and Genetic Diseases at ASGCT 28th Annual Meeting
    From Ensoma
    Via Business Wire
    News headline image
    Ensoma Receives Rare Pediatric Disease and Orphan Drug Designations for EN-374 for Treatment of Chronic Granulomatous Disease
    From Ensoma
    Via Business Wire
    News headline image
    Ensoma Unveils Three Programs Leveraging In Vivo Hematopoietic Stem Cell Engineering Platform to Target Genetic, Immune and Oncological Diseases
    From Ensoma
    Via Business Wire
    News headline image
    Ensoma Appoints Accomplished Deal Maker Jon Garen as Chief Corporate Development and Business Officer
    From Ensoma
    Via Business Wire
    News headline image
    Ensoma Appoints Accomplished Company Builder and Product Developer, Jim Burns, Ph.D., as Chief Executive Officer
    From Ensoma
    Via Business Wire
    News headline image
    Ensoma Closes Series B Extension, Bringing Total Round to $135 Million
    From Ensoma
    Via Business Wire
    News headline image
    Ensoma Announces Closing of Twelve Bio Acquisition
    From Ensoma
    Via Business Wire
    News headline image
    Ensoma Announces $85 Million Financing and Agreement to Acquire Twelve Bio to Advance Portfolio of In Vivo Engineered Cellular Medicines
    From Ensoma
    Via Business Wire
    News headline image
    Ensoma Strengthens Scientific Advisory Board with Leaders in Oncology and Primary Immune Deficiencies
    From Ensoma
    Via Business Wire
    News headline image
    Ensoma Appoints Cell and Gene Therapy Pioneer Emile Nuwaysir, Ph.D., as Chief Executive Officer
    From Ensoma
    Via Business Wire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.